NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Forecast & News

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.07. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,013.45% and a negative return on equity of 110.20%. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syndax Pharmaceuticals.

6 brokers have issued 1-year price targets for Syndax Pharmaceuticals' shares. Their forecasts range from $5.00 to $19.00. On average, they expect Syndax Pharmaceuticals' share price to reach $14.20 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

News headlines about SNDX stock have trended extremely negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Syndax Pharmaceuticals.

Some companies that are related to Syndax Pharmaceuticals include Akebia Therapeutics (AKBA), NextCure (NXTC), Opko Health (OPK), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Phibro Animal Health (PAHC), Kiniksa Pharmaceuticals (KNSA), Odonate Therapeutics (ODT), Dermira (DERM), Karyopharm Therapeutics (KPTI), Myovant Sciences (MYOV), Gossamer Bio (GOSS), I-Mab (ARQT), Phathom Pharmaceuticals (PHAT) and Achillion Pharmaceuticals (ACHN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Clearside Biomedical (CLSD), Verastem (VSTM), Cara Therapeutics (CARA), Micron Technology (MU) and TG Therapeutics (TGTX).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.83%), State Street Corp (1.62%), Geode Capital Management LLC (1.11%), Boxer Capital LLC (0.92%), Panagora Asset Management Inc. (0.48%) and Oxford Asset Management LLP (0.38%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.

SNDX stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Panagora Asset Management Inc., Acadian Asset Management LLC, Oxford Asset Management LLP, New York State Common Retirement Fund and Renaissance Technologies LLC. View Insider Buying and Selling for Syndax Pharmaceuticals.

SNDX stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Goldman Sachs Group Inc., State Street Corp, Jacobs Levy Equity Management Inc., California Public Employees Retirement System, Geode Capital Management LLC, Barclays PLC and Algert Global LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $10.66.

Syndax Pharmaceuticals has a market capitalization of $289.31 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.

The official website for Syndax Pharmaceuticals is http://www.syndax.com/.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]